Abstrait

Role of immunotherapy in non-small cell lung cancer

Kari Gioux

Immunotherapy has emerged as a promising treatment strategy for non-small cell lung cancer (NSCLC), a type of lung cancer that accounts for the majority of cases. NSCLC cells can evade the immune system, but immunotherapy drugs such as checkpoint inhibitors can help to activate T cells and enhance immune response against cancer cells. While not all patients respond to immunotherapy, those who do often experience durable responses with fewer side effects than traditional chemotherapy. Ongoing research is focused on identifying biomarkers that can predict response to immunotherapy and developing combination therapies to further improve outcomes for patients with NSCLC.